comparemela.com

Page 22 - Glenmark News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Glenmark Specialty S A and Lotus International Pte Ltd enter into exclusive licensing agreement for commercializing Ryaltris Nasal Spray in Singapore, Hong Kong and Vietnam

Mumbai (Maharashtra) [India], January 20 (ANI/PRNewswire): Glenmark Pharmaceuticals Ltd

United statesHong kongUnited kingdomRepublic ofCzech republicSouth africaSouth koreaRobert crockartPetar vazharovUdaykumar murthySeqirus ptyYuhan corporationLotus pharmaceutical co ltdCorporate communicationsLotus international pteGlenmark pharmaceuticals limited

Glenmark Pharmaceuticals receives ANDA tentative approval for Regadenoson Injection, 0 4 mg/5 mL (0 08 mg/mL) Single-Dose Pre-Filled Syringe

Mumbai (Maharashtra) [India], January 17 (ANI/PRNewswire): Glenmark Pharmaceuticals Inc., USA (Glenmark) has received tentative approval by the United States Food & Drug Administration (U.S

United statesStates glenmarkUdaykumar murthyCorporate communicationsGlenmark pharmaceuticals limitedUnited states food drug administrationGlenmark pharmaceuticals incCompany rankingsAstellas us incNational sales perspectivesUnited states foodDrug administrationRegadenoson injectionSingle dose pre filled syringeLexiscan injectionSales perspectives

Glenmark s subsidiary Ichnos Sciences inks agreement with Almirall

Almirall is granted exclusive global rights to develop and commercialise ISB 880 for use in autoimmune diseases

Glenmark pharmaIchnos sciencesGlenmark pharmaIchnos sciences

Glenmark becomes the first company to launch Type 2 Diabetes fixed-dose combination drug in India

Glenmark received approval for the drug from the Drug Controller General of India for manufacturing and marketing in late September 2021.

Glenmark remogliflozinAlok malikGroup viceInternational diabetes federationDrug controller generalGroup vice presidentBusiness headFixed dose combinationType a

Glenmark brings fixed-dose combination diabetes drug in India

The combination contains Remogliflozin (100 mg) + Vildagliptin (50 mg) + Metformin (500/1000 mg) in a fixed-dose and must be taken twice daily to improve glycemic control in patients

Remogliflozin etabonateGlenmark remogliflozinGlucose coGlenmark pharmaceuticalsSodium glucose co transporter inhibitorDipeptidyl peptidaseType 2 diabetes

vimarsana © 2020. All Rights Reserved.